Wnt/Β-Catenin and Sex Hormone Signaling In Endometrial Homeostasis and Cancer by Wang, Yongyi et al.
www.impactjournals.com/oncotarget/  Oncotarget, November, Vol.1, No 7
Oncotarget 2010; 1:  674 - 684 www.impactjournals.com/oncotarget 674
Wnt/Β-Catenin  and  Sex  Hormone  Signaling  in  Endometrial 
Homeostasis and Cancer
Yongyi Wang1,2, Marten van der Zee1,2, Riccardo Fodde2, Leen J Blok1
1 Department of Obstetrics & Gynaecology, Josephine Nefkens Institute, Erasmus University Medical Center Rotterdam, PO 
Box 2040, 3000 CA Rotterdam, The Netherlands
2 Departments of Pathology, Josephine Nefkens Institute, Erasmus University Medical Center Rotterdam, PO Box 2040, 3000 
CA Rotterdam, The Netherlands 
Correspondence to: Leen J Blok, e-mail: l.blok@erasmusmc.nl
Keywords:  Wnt/β-catenin, estradiol, progesterone, endometrium
Received: September 30, 2010, Accepted: October 11, 2010, Published: October 12, 2010
Copyright: © Wang et al.  This is an open-access article distributed under the terms of the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
AbstrAct:
A delicate balance between estrogen and progestagen signaling underlies proper 
functioning of the female reproductive tract and, in particular, the monthly re- and 
degenerative phases characteristic of the menstrual cycle. Here, we propose that the 
canonical Wnt/β-catenin signaling pathway may underlie this finely tuned hormonal 
equilibrium  in  endometrial  homeostasis  and,  upon  its  constitutive  activation, 
lead  to  neoplastic  transformation  of  the  endometrium.  During  the  menstrual 
cycle,  estradiol  will  enhance  Wnt/β-catenin  signaling  in  the  proliferative  phase, 
while  progesterone  inhibits  Wnt/β-catenin  signaling,  thus  restraining  estrogens’ 
proliferative actions, during the secretory phase. In case of enhanced or unopposed 
estrogen signaling, constitutive activation of Wnt/β-catenin signaling will trigger 
endometrial  hyperplasia,  which  may  develop  further  into  endometrial  cancer.
sex hormone signAling in the 
endometrium
The inner layer of the human uterus, the endometrium 
is a dynamic tissue that undergoes hundreds of cycles 
of proliferation, differentiation and shedding during a 
woman’s reproductive years [1]. The endometrium can be 
divided into two layers, the functionalis and the basalis. 
Whereas the functionalis layer comprises the upper 
two-thirds of the endometrium and is shedded during 
menstruation, the basalis includes the lower one-third 
which remains intact and is responsible for producing a 
new functionalis during each subsequent menstrual cycle 
[1] [2]. 
It is the fine balance between the activities of the 
two female sex hormones, estradiol and progesterone, 
which determines lineage faith in the endometrium. 
During the first two weeks of the menstrual cycle the 
thecal cells of the ovary produce large amounts of 
estradiol. Simultaneously, endometrial estrogen receptor 
(ER) levels (mainly ERα) are increased [3]. Upon ligand 
binding, ER dimers will translocate to the nucleus where 
they activate transcription of downstream target genes 
(e.g.  insulin  like  growth  factor;  IGF-1), that stimulate 
endometrial proliferation [4]. Later, during the third and 
fourth week of the menstrual cycle, the corpus luteum 
starts producing progesterone thus inhibiting estradiol-
induced proliferation of endometrial cells and stimulating 
cellular differentiation [5] [6]. If no fertilized oocytes 
are implanted in the uterus, the corpus luteum cannot be 
maintained due to lack of human chorion gonadotropine 
(HCG), and both estrogen and progesterone levels will 
decline. Withdrawal of progesterone leads to endometrial 
cell apoptosis and tissue breakdown of the functionalis of 
the endometrium, resulting in its shedding from the uterus 
[7]. 
The inhibition of estrogens’ mitotic activity exerted 
by progesterone is of clinical relevance as unopposed or 
increased estrogen action in women is a well-established 
risk factor for endometrial cancer [8] [9]. 
unbalanced sex hormone signaling can induce 
endometrial cancer
Endometrial cancer is one of the most common 
cancers of the female genital tract [10]. It accounts each Oncotarget 2010; 1:  674 - 684 675 www.impactjournals.com/oncotarget
year for approximately 142.000 new cases diagnosed 
worldwide, and for 42.000 deaths [11] [12]. Endometrial 
cancer is the seventh most common malignant disorder 
and its incidence is expected to increase in the near future 
due to the increase in life span expectancy and obesity 
[13]. 
Based on epidemiology, conventional histopathology, 
and clinical behavior, endometrial carcinoma can be 
divided into two subtypes. Type I endometrial cancer, 
comprising approximately 85% of the total endometrial 
carcinoma burden among western societies, resembles 
normal endometrial hyperplasia in morphology and is 
associated with increased or unopposed estrogen signaling 
[12]. Type I endometrial cancer often shows mutations in 
the PTEN and in DNA mismatch repair genes (MLH1, 
MSH2, MSH6). Also, oncogenic mutations in KRAS and/
or CTNNB1 (β-catenin) are recognized major alterations 
[14] [15] [16]. Type II endometrial cancer occurs 
predominantly in older post-menopausal women, is not 
correlated to increased estrogen exposure, and is generally 
associated with a poorer prognosis. Type II endometrial 
cancers often show mutations in TP53 and ERBB2 (Her-2/
neu) [12] [15] [16].
In western, industrialized countries, two large groups 
of women are at increased risk of developing endometrial 
cancer: (i) women with significant overweight [13], and 
(ii) those receiving tamoxifen for breast cancer treatment 
[17]. Tamoxifen is a selective estrogen receptor modulator 
(SERM) acting as an antiestrogen in mammary tissue, but 
showing  estrogenic  activity  in  the  endometrium  [18]. 
Currently, it is estimated that up to 40% of all endometrial 
cancers  could  be  related  to  obesity  [13].  Since  the 
prevalence of obesity is increasing, the incidence of 
obesity-related endometrial cancer is also on the rise [19]. 
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Figure 1: inhibition of estrogen-induced genes by progesterone. The data employed in this figure were obtained by combining 
endometrial gene expression profiles from postmenopausal women after no treatment (C), 21-day treatment with estradiol (E), or estradiol + 
medroxyprogesterone acetate (E+P) [22], with gene expression profiles from the proliferative endometrium (PE), early secretory endometrium 
(ESE), mid secretory endometrium (MSE), or late secretory endometrium (LSE) [4]. The bars represent the relative expression levels of the 
indicated genes under the indicated conditions. For this figure the twenty most significantly estrogen regulated genes are shown. The three 
highlighted gene-names are those discussed in depth in the text.Oncotarget 2010; 1:  674 - 684 676 www.impactjournals.com/oncotarget
Additional risk factors for the development of endometrial 
cancer  include:  polycystic  ovarian  syndrome,  skipping 
menstrual periods, being nulliparous, late menopause 
onset, and the use of unopposed estrogen as hormone 
substitution therapy [20]. Hence, enhanced estrogen 
signaling for prolonged periods of time, also as the result 
of insufficient progesterone levels, represents the main 
risk factor in endometrial cancer. 
Progesterone antagonizes the proliferative activity 
of estrogen by inducing epithelial and stromal cell 
differentiation in the endometrium [21] [22]. In fact, 
although progesterone (in the form of medroxyprogesterone 
acetate (MPA)) can be used for the palliative treatment 
of well-advanced and recurrent endometrial cancer, this 
treatment has a modest response rate (15-25%) [23]. In 
contrast, when progesterone, is employed as a primary 
treatment (e.g. in pre-menopausal women suffering from 
well-differentiated endometrial cancer and determined 
to preserve fertility), response rates are considerably 
improved (up to 60% or more) [24] [25]. 
Progesterone inhibition of estrogen-induced 
proliferation
The mechanisms by which progesterone induces 
its anti-proliferative effect on the endometrium are still 
largely  unknown.  Several  studies  have  shown  a  direct 
effect of progesterone on estrogen receptor signaling 
and expression levels [26], while others show that 
progesterone affects the availability of bioactive estrogens 
[27] [28] [29]. Furthermore, differential expression of the 
progesterone  receptor  (PR)  isoforms  (PRA  and  PRB) 
and the relative expression levels of ERα compared to 
ERβ  could  also  play  a  role  in  controlling  endometrial 
proliferation during the menstrual cycle [30] [27].
In order to investigate in more detail the molecular 
mechanism(s) underlying progesterone-driven inhibition 
of estrogen signaling, expression profiling analysis was 
conducted on endometrial tissue specimens obtained 
from  postmenopausal  women  treated  for  three  weeks 
with  estrogens  (E-only)  or  estrogens+progestagens 
(E+P)  and  compared  to  untreated  controls  [21]  [22]. 
The endometrial gene profiles obtained from this study 
were also compared with endometrial gene expression 
levels of untreated women during the different stages 
of  the  menstrual  cycle  [4].  Upon  reviewing  regulation 
of expression of the twenty most significantly estrogen-
regulated genes (Fig. 1), it was observed that most of 
them were completely counterbalanced by concurrent 
administration of progestagens (E+P). However, estrogen-
induced  upregulation  of  specific  genes  (e.g.  IGF1 and 
IGFBP5) is only partly counterbalanced by progestagens, 
whereas in other cases (e.g. SCGB1D2) the increase of 
expression level upon estrogen signaling is not at all 
counterbalanced by progestagens. Notably, these genes 
also behave differently during the menstrual cycle: IGF1 
and IGFB5 are upregulated during the proliferative, early 
and mid secretory phases of the menstrual cycle, whereas 
SCGB1D2 is upregulated exclusively during the early and 
mid secretory phases (Fig. 1). 
Next to gene profiling studies, immunohistochemical 
analysis of PRA/PRB and ERα expression were performed 
together with measurements of estrogen availability [21]. 
These investigations revealed that besides a small increase 
in  PRA/PRB  levels  in  glandular  cells  upon  treatment 
with E-only, no pronounced differences in ERα and PR 
expression levels were observed between the E-only and 
the E+P group [21]. Furthermore, in order to fully asses 
estrogen signaling, next to the biologically most potent 
estrogen, estradiol (E2), the less active estradiol precursor, 
estrone (E1), as well as its inactivated form, sulfated 
estrone  (E1S),  were  measured  [28]  [31]  [32].  It  was 
observed that both in sera and in uterine tissues, estradiol, 
estrone and sulfated estrone were increased as a result 
of E-only and E+P treatment, though with no significant 
difference  between  the  treatment  groups  [32]  These 
studies seem to indicate that progestagenic regulation of 
estrogen signaling at the receptor level and at the level 
of ligand availability is not the major mechanism through 
which progesterone counterbalances estrogen signaling 
during the menstrual cycle, and additional molecular 
mechanisms are likely to play a role. 
In literature there are a number of reports implicating 
an important role for Wnt/β-catenin signaling in regulating 
endometrial proliferation and differentiation. For example, 
the  activity  of  Wnt/β-catenin  signaling  was  observed 
to change between different stages of the menstrual 
cycle  [33]  and  plays  an  important  role  in  preparing 
the  endometrium  for  embryo  implantation  [34]  and 
subsequent placental formation [35]. Furthermore, Wnt/β-
catenin signaling is often found activated in endometrial 
cancer  [14]  [36]  and,  upon  reviewing  regulation  of 
estrogen and progesterone regulated genes [21] [22] 
[4],  it  was  also  observed  that  a  significant  number  of 
downstream targets and components of the Wnt/β-catenin 
signaling pathway were regulated [37]. Moreover, some 
of the sex hormone-regulated downstream targets and 
components of the Wnt/β-catenin signaling pathway have 
also been implicated in endometrial carcinogenesis: both 
FOXO1 and CDH1 (E-cadherin) expression is decreased 
in endometrial cancer and is induced by progesterone [38] 
[39] while Survivin (BIRC5) is expressed at high levels 
in endometrial cancer and upregulated by estradiol [40]. 
Based  on  these  observations,  a  role  for  Wnt/β-catenin 
signaling downstream from sex hormone signaling in the 
endometrium was hypothesized and will be discussed in 
more detail in the next paragraphs.Oncotarget 2010; 1:  674 - 684 677 www.impactjournals.com/oncotarget
the relAtionshiP between sex 
hormone  and  Wnt/β-catenin 
signAling in the endometrium
Central in canonical Wnt signaling is the destruction 
complex, a multi-protein complex consisting of the scaffold 
proteins  AXIN1  and  AXIN2  (conductin),  β-catenin 
(CTNNB1),  the  tumor  suppressor  APC  (adenomatosis 
polyposis coli) and the Ser-Thr kinases CK1 (casein kinase 
I) and GSK3β (glycogen synthase kinase 3 beta) [41]. In 
the absence of Wnt ligands, formation of the destruction 
complex  triggers  Thr/Ser-phosphorylation  of  β-catenin 
by CK1 and GSK3β, and its subsequent ubiquitination 
and proteasomal degradation. Upon Wnt signaling, the 
formation of the destruction complex is inhibited thus 
leading to cytoplasmic accumulation of β-catenin and its 
nuclear translocation [42]. Once in the nucleus, β-catenin 
interacts with members of the TCF/LEF transcription 
factor family, thus regulating the expression of a broad 
spectrum  of  Wnt  downstream  target  genes  [42]  [43] 
[44]. The latter include genes encoding for proteins with 
a central role in cell proliferation and survival such as 
cyclin D1 (CCND1) and c-MYC, in addition to a broad 
spectrum of other cellular functions i.e. cellular migration 
(e.g. CD44), cell adhesion (CDH1), extracellular matrix 
(MMP7) and many others [42] [45].
The central role of Wnt/β-catenin signaling in the 
regulation of tissue homeostasis has been extensively 
investigated for the gut [42] [46]. Along the intestinal 
tract, stem cells are located at the bottom of the crypts 
of Lieberkuhn where they give rise to new stem cells and 
to proliferating progenitor cells (transient amplifying, 
TA, cells) [47]. These progenitor cells actively divide and 
produce new cells that are pushed up along the flank of 
the crypt towards the villus and eventually differentiate 
into Goblet cells, enteroendocrine cells and absorptive 
epithelial cells [48]. A somewhat similar process seems 
to take place in the endometrium, where estrogen receptor 
activation in the basalis stimulates endometrial cell 
proliferation during the first two weeks of the menstrual 
cycle, thus giving rise to the functionalis. In week three 
and four of the menstrual cycle, the corpus luteum will 
produce progesterone, which reduces estrogens-driven 
proliferation and induces differentiation of the functionalis 
thus preparing the endometrium for implantation of the 
fertilized oocyte around day 20 - 22 of the menstrual cycle. 
Wnt/β-catenin signaling activity along the crypt-villus 
axis of the intestine follows a decreasing gradient from the 
stem cell (SC) and proliferative (TA) compartment to the 
more differentiated compartment [49]. In the endometrium 
Wnt/β-catenin signaling has also been suggested to play a 
role in regulating proliferation and differentiation during 
the menstrual cycle. Nei et al. [33] observed that in the 
human  endometrium,  nuclear  β-catenin  was  clearly 
enhanced during the proliferative phase of the menstrual 
cycle, while it was mostly found in the cytoplasm and at 
the cell membrane during the secretory phase. Recently, 
it was also observed that estradiol induces stabilization 
of intracellular β-catenin in the endometrium, and, upon 
inhibition of Wnt signaling (by using adenoviral SFRP2), 
estradiol-induced proliferation was abolished [50]. In two 
other studies [51] [52], LiCl was administered through 
the drinking water of mice to inhibit GSK3β activity and 
thereby activate Wnt signaling. LiCl-treated animals were 
characterized by increased proliferation and hyperplasia 
of the endometrium, thus mimicking sustained estrogen 
signaling. 
In summary, it seems likely that, during the menstrual 
cycle,  sex  hormones  can  modulate  Wnt/β-catenin 
signaling to maintain the balance between proliferation 
and differentiation. 
estradiol regulation of Wnt/β-catenin signaling
The putative mechanisms underlying estrogen-
mediated  Wnt/β-catenin  activation  in  the  uterus  are 
at present poorly understood. A direct effect of ERα as 
a transcription factor on the expression of Wnt ligands, 
modulators and targets has been described by many 
authors: the ligands Wnt4, Wnt5A and Wnt7A have been 
shown to be induced by estradiol [53] [54] [50] [55] [56]; 
the Wnt inhibitor DKK1 was shown to be inhibited by 
estrogens in bone forming osteoblasts [57] and in the 
hippocampal  CA1  region  [58]  and  last,  the Wnt-target 
gene WISP2 (Wnt-1 induced signaling pathway protein 2) 
was shown to be upregulated through direct interaction of 
activated ERα with its promoter region in human breast 
cancer cells [59]. 
ERα, however, can also function as a transcriptional 
modulator without directly binding to DNA sequences in 
the promoter region of the affected genes. For example, 
Shi et al [60] could show that EZH2 (the polycomb group 
protein enhancer of zeste homolog 2) physically interacts 
with  ERα  and  β-catenin.  Hence,  estradiol  can  affect 
the transcription of Wnt/β-catenin target genes without 
directly interacting with estrogen response elements at the 
DNA level. 
Furthermore,  ERα  has  also  been  observed  to 
associate with important growth factor pathways such 
as the PI3K pathway thus indirectly cross-talking with 
canonical Wnt  signaling  [61]  [62].  Binding  of  ERα  to 
p85 (PIK3R2), the regulatory subunit of PI3K, activates 
AKT1 which results in inhibition of GSK-3β. This, in 
turn, prevents N-terminal Ser/Thr phosphorylation of 
β-catenin,  enhances  its  intracellular  stabilization  and 
eventual allowes for translocation to the nucleus, where 
it complexes with members of the TCF/LEF transcription 
factor family and lead to the activation of Wnt target genes 
[63] [64] (Fig. 2A and Fig 3). 
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Figure 2: estrogen (a) and progestagen (B) regulation of Wnt/β-catenin signaling in the endometrium. Oncotarget 2010; 1:  674 - 684 679 www.impactjournals.com/oncotarget
signaling
A role for progesterone in regulating Wnt/β-catenin 
signaling was suggested by Kao et al. [65] and by Tulac 
et al. [66] who observed a profound progesterone-specific 
increase  in  expression  of  the  Wnt/β-catenin  signaling 
inhibitor  DKK1 in endometrial stroma cells during 
the  secretory  phase  of  the  menstrual  cycle.  Using  the 
antiprogestagen  mefipristone  (RU486),  Catalano  et  al. 
[67] could indeed confirm progestagen regulation of many 
Wnt/β-catenin pathway components. Furthermore, Kane 
at al. [68] subsequently showed that TGFβ1 attenuates 
both the expression of PR and DKK1 in differentiated 
endometrial  stromal  cells  corroborating  a  close  link 
between progesterone and Wnt/β-catenin signaling. 
Recently, our group has followed up on these 
observations  [37]  and  could  show  that  progesterone 
efficiently  inhibited  the  expression  of  a  Wnt/β-catenin 
signaling  reporter  plasmid  (TOP/FOPflash)  in  the 
Ishikawa endometrial cancer cell line by induction of the 
Wnt/β-catenin  inhibitors  DKK1 [66] and FOXO1  [38]. 
Furthermore, when induction of both DKK1 and FOXO1 
was prevented, progesterone inhibition of Wnt signaling 
was also partly circumvented. FOXO1, in this respect, is 
an interesting molecule, as it has been shown to physically 
interact with the progesterone receptor to coordinate cell 
cycle regulation and differentiation of human endometrial 
stromal cells [69]. Furthermore, FOXO1 is also able to 
interact with β-catenin [70] [71], thus possibly directly 
inhibiting Wnt/β-catenin signaling [72]. 
Another pathway likely to play a role in regulating 
the  interplay  between  progesterone  and  Wnt/β-catenin 
signaling is Hedgehog (Hh). Combined endometrial 
microarray data from different stages of the menstrual 
cycle [4] and from E-only or E+P treated patients [22] 
indicated profound sex hormone regulation of Hh 
signaling. The Hedgehog ligand IHH (Indian hedgehog), 
its receptor PTCH, and the transcription factor and target 
gene GLI1 are all up-regulated upon estrogen signaling 
and downregulated by progesterone during the menstrual 
cycle. Furthermore, it has been shown that when IHH 
expression is impaired, the downstream effects of 
progesterone  are  lost  in  the  uterus  [73]. As  indicated, 
progesterone itself downregulates Hh signaling in the 
uterus and it has been shown that Wnt/β-catenin signaling 
may act downstream to Indian hedgehog signaling [74]. 
Recently  the  link  between  Hedgehog  and  Wnt/β-
catenin  signaling  has  also  been  confirmed  for  atypical 
endometrial hyperplasia and endometrial cancer: in 
hyperplasia and in well differentiated endometrial cancers 
GLI1  overexpression  overlaps  with  β-catenin  nuclear 
immunoreactivity [75]. Because our own data on staining 
for the Wnt target gene CD44 indicated that progesterone 
can  also  act  as  a  profound  inhibitor  of  Wnt/β-catenin 
signaling  in vivo in hyperplasia as well as in well 
differentiated endometrial cancer, a physiological and 
functional link between progesterone, hedgehog and Wnt/
β-catenin signaling seems plausible. (Fig. 2B and Fig. 3)
role oF wnt signAling in 
endometriAl cAncer
Gene mutations leading to constitutive activation 
of canonical Wnt signaling have been found in many 
different cancer types (e.g. breast, colon, stomach, liver, 
ovary skin etc). Also in the case of endometrial cancer, 
activation  of  Wnt/β-catenin  signaling  is  likely  to  play 
an  important  role  in  early  tumorigenesis  [14]  [36].  A 
substantial fraction of well differentiated endometriod 
carcinomas  (Type  I)  cases  (31%:  [76];  85%:  [77]) 
show  nuclear  β-catenin  staining  (Fig.  4). Accordingly, 
loss- and gain-of-function mutations in members of the 
Wnt/β-catenin signaling pathway known to act as tumor 
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Figure 3: hormonal and morphological changes during 
the normal menstrual cycle (A) and in case of increased 
estrogen activity (b). In case of enhanced or unopposed estrogen 
signaling, the endometrium may develop hyperplasia, which may 
eventually develop further into endometrial cancer. Oncotarget 2010; 1:  674 - 684 680 www.impactjournals.com/oncotarget
suppressors (APC) and oncogenes (β-catenin) have also 
been identified. β-catenin activating mutations at its GSK-
3β  binding  consensus  site  located  within  exon  3  have 
been identified in 15-40 % of endometrial tumors [78] 
[79], whereas LOH at the APC locus was observed in 24 
% of the cases with nuclear β-catenin staining [80]. APC 
mutation analysis showed truncating mutations in 10% 
of all endometrial cancers [81]. Moreover, the APC A1 
promoter was found to be hypermethylated in 46.6% of 
endometrial cancers with nuclear β-catenin [80], often in 
correlation with micro-satellite instability [82]. Notably, 
these somatic mutations in members of the canonical Wnt 
pathway were preferentially found in Type I endometrial 
cancer, which accounts for about 85% of the total number 
of endometrial cancer cases. Enhanced estrogen signaling 
over a prolonged period of time is believed to be a causative 
factor for Type I endometrial cancer [9]. Hence, although 
continuous  estrogen  induced  Wnt/β-catenin  signaling 
may represent an early step in endometrial tumorigenesis, 
tumor progression and malignant transformation seem 
to additionally require somatic mutations leading to the 
constitutive activation of the pathway (Fig. 3).
current  investigations  into  the  role  of  Wnt/β-
catenin signaling in endometrial carcinogenesis. 
Enhanced or unopposed estrogen signaling is the 
most important risk factor for endometrial hyperplasia and 
endometrial cancer. In view of the observations according 
to which i. Wnt/β-catenin signaling plays a central role 
in endometrial homeostasis, ii. it possibly represents 
one of the downstream effectors of estrogen signaling, 
and  iii.  its  constitutive  activation  is  likely  to  underlie 
malignant transformation in the uterus, it is important 
to assess whether canonical Wnt can trigger endometrial 
hyperplasia and cancer in the absence of enhanced 
estrogen signaling. In other words, among the allegedly 
broad spectrum of downstream effectors of estrogen 
signaling, does constitutive Wnt/β-catenin activation play 
a rate-limiting role for endometrial malignancies?
To this aim, several genetically engineered mouse 
models have been employed. Tanwar et al. [83] investigated 
the effects of conditional Wnt signaling activation in the 
uterus by Amhr2-Cre-driven oncogenic activation of 
β-catenin (Ctnnb1tm1Mmt/+). The Amhr2 gene is expressed 
as of embryonic day 12.5 onwards in mesenchymal cells 
surrounding the Mullerian duct and in adult mice in the 
myometrium. The corresponding Amhr2Cre/+;Ctnnb1tm1Mmt/+ 
mice develop myometrial hyperplasia and mesenchymal 
tumors (similar to leiomyomas) and endometrial 
sarcomas. Furthermore, hyperplasia of endometrial glands 
was occasionally observed in the uterus, suggesting that 
mesenchymal activation of Wnt/β-catenin signaling plays 
a role in the early events of epithelial tumorigenesis in the 
endometrium. Jeong et al. [84] employed Pgr-Cre to drive 
oncogenic activation of β-catenin (PgrCre/+;Ctnnb1f(Ex3)/+) 
and of canonical Wnt signaling in a broad spectrum of 
uterine cells (endometrium + myometrium). These authors 
could show that activation of Wnt/β-catenin signaling in 
the uterus resulted in enhanced proliferation of glandular 
epithelial  cells,  endometrial  hyperplasia  at  6  weeks  of 
age, and in defective estrogen signaling, though not in 
endometrial cancer. These results suggest that constitutive 
activation  of  Wnt/β-catenin  signaling  on  its  own  is 
insufficient  for  endometrial  cancer  onset  and  possibly 
that the synergistic action of additional downstream 
effectors of estrogen signaling are necessary for full-
blown malignant transformation. However, as predicted 
by the ”just-right” signaling model [85] [86], different 
levels of pathway activation may differently trigger 
tumorigenesis in distinct tissues. Therefore, it would be of 
interest to investigate the consequences of hypomorphic 
mutations in members of the Wnt pathway other than 
β-catenin  whose  oncogenic  activation  invariably  leads 
to extremely high Wnt signaling levels. By inducing Apc 
mutations in the myometrium [87], we recently observed 
defects in the myometrial layer of the uterus, where a 
significant loss of muscle fibers was apparent [Wang et al, 
submitted). Likewise, we also employed Pgr-Cre to drive 
loss of Apc function in epithelial cells of the endometrium 
and in myometrial cells. Also in this case, muscular 
defects were apparent with invasion of endometrial 
glands and stroma into the muscular layer. Notably, we 
also observed hyperplasia and early stage endometrial 
cancer [manuscript in preparation). Hence, it is possible 
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Figure 4: nuclear β-catenin accumulation in well differentiated endometrial cancer. Immunohistochemical staining for β-catenin 
of type I endometrial cancer showing areas with nuclear β-catenin accumulation.Oncotarget 2010; 1:  674 - 684 681 www.impactjournals.com/oncotarget
that  “just-right”  levels  of  Wnt/β-catenin  signaling  are 
sufficient to trigger tumor initiation in the endometrium in 
a dosage- and context-dependent fashion.
conclusions
In this review we discussed the role of estrogens 
and  progestagens  in  the  regulation  of  Wnt/β-catenin 
signaling as well as the involvement of activated Wnt/β-
catenin signaling in the development of endometrial 
cancer. Evidence indicates that estrogens can induce 
Wnt/β-catenin signaling and that enhanced or unopposed 
estrogen  signaling,  as  well  as  activated  Wnt/β-catenin 
signaling may underlie endometrial hyperplasia and 
cancer. Furthermore, progesterone was shown to be a 
strong inhibitor of Wnt/β-catenin signaling. The latter is 
of clinical relevance as it is well known that progesterone 
can inhibit endometrial hyperplasia and well differentiated 
endometrial cancer growth. 
These observations place Wnt/β-catenin signaling at 
the center of physiological regulation of the menstrual cycle 
and point at a central functional role for its uncontrolled 
activation in endometrial carcinogenesis. Although 
Wnt/β-catenin  signaling  inhibitors  (e.g.  CGP049090, 
PKF115-584 [88] and XAV939 [89]) have not yet been 
introduced  into  clinical  practice  and  likewise  have  not 
been considered for endometrial cancer treatment, the 
experimental data here summarized may lay the basis 
for future tailor-made therapies based on members of the 
canonical Wnt pathway or its downstream targets.
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